Conference PaperPDF Available

Reviewing the Well's Criteria in the Context of COVID-19 Pandemic

  • Independent researcher


This is a conference paper about the need for revised Well´s criteria in the context of COVID-19 pandemic.
Journal of Infectious Diseases and Research
JIDR, 5(S1): 04
ISSN: 2688-6537
Abstract: Open Access
SciTech Central Inc.
J Infect Dis Res (JIDR) 184
Reviewing the Wells Criteria in the Context of COVID-19 Pandemic
Domina Petric*
*University Hospital Center Split, Croatia.
Published July 07, 2022
The Wells criteria for pulmonary embolism (PE) is a risk stratification score and clinical decision rule to estimate the
probability for acute PE in patients in which history and examination suggests acute PE is a diagnostic possibility. Wells
criteria include clinical symptoms of deep venous thrombosis (DVT), such as leg swelling, pain with palpation (3 points),
other diagnosis less likely than pulmonary embolism (3 points), heart rate >100 beats per minute (1.5 points), immobilization
(≥3 days) or surgery in the previous four weeks (1.5 points), previous DVT/PE (1.5 points), hemoptysis (1 point) and
malignancy (1 point). According to traditional clinical probability assessment the likelihood of diagnosing PE is high if the
score is more than 6, moderate for the score between 2 and 6, and low if the score is less than 2. According to modified Wells
criteria PE is likely if the score is more than 4, and unlikely if the score is less than 4. Both natural spike protein (SARS-
CoV-2 infection) and artificial spike protein (spike-protein based vaccines) may be associated with an increased risk for the
development of thromboembolism. Studies have shown that spike protein alone can damage vascular endothelial cells by
down-regulating ACE2 and consequently inhibiting mitochondrial function and that spike-induced degradation of endothelial
junctional proteins affects endothelial barrier function, which causes vascular damage. Results of a study detected a safety
signal for venous thromboembolism (VTE) after first-dose of BNT162b2 (Pfizer/BioNTech) and a similar estimate was seen
for first-dose of ChAdOx1 (AstraZeneca/Oxford). There was a 1.3-fold increase in the rate of VTE after first-dose of
BNT162b2 compared with an 8-fold increase after diagnosis of COVID-19. I propose that both recent (in the previous 4
weeks) COVID-19 infection and spike-protein based vaccination may be included in the Wells criteria and scored 1 point for
COVID-19 and 0.5 points for recent spike-protein based vaccination in a patient with symptoms typical for pulmonary
embolism and/or deep venous thrombosis.
Keywords: COVID-19, Wells criteria, Pulmonary embolism, Deep venous thrombosis
Abbreviations: PE: Pulmonary Embolism; DVT: Deep Venous Thrombosis; VTE: Venous Thromboembolism
Corresponding author: Domina Petric, University Hospital Center Split, Croatia, Email:
Citation: Petric D. (2022) Reviewing the Well’s Criteria in the Context of COVID-19 Pandemic. J Infect Dis Res, 5(S1): 04.
Copyright: ©2022 Petric D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.